Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes

被引:351
作者
Rosenstock, Julio [1 ]
Aggarwal, Naresh [2 ]
Polidori, David [3 ]
Zhao, Yue [4 ]
Arbit, Deborah [4 ]
Usiskin, Keith [4 ]
Capuano, George [4 ]
Canovatchel, William [4 ]
机构
[1] Dallas Diabet & Endocrine Ctr Med City, Dallas, TX USA
[2] Aggarwal & Associates Ltd, Brampton, ON, Canada
[3] Janssen Global Serv LLC, La Jolla, CA USA
[4] Janssen Global Serv LLC, Raritan, NJ USA
关键词
INSULIN-SECRETION; HYPERGLYCEMIA; PREVALENCE; TRANSPORT; MELLITUS;
D O I
10.2337/dc11-1926
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE-To evaluate the effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes mellitus inadequately controlled with metformin monotherapy. RESEARCH DESIGN AND METHODS-This was a double-blind, placebo-controlled, parallel-group, multicenter, dose-ranging study in 451 subjects randomized to canagliflozin 50, 100, 200, or 300 mg once daily (QD) or 300 mg twice daily (BID), sitagliptin 100 mg QD, or placebo. Primary end point was change in A1C from baseline through week 12. Secondary end points included change in fasting plasma glucose (FPG), body weight, and overnight urinary glucose-to-creatinine ratio. Safety and tolerability were also assessed. RESULTS-Canagliflozin was associated with significant reductions in A1C from baseline (7.6-8.0%) to week 12: -0.79, -0.76, -0.70, -0.92, and -0.95% for canagliflozin 50, 100, 200, 300 mg QD and 300 mg BID, respectively, versus -0.22% for placebo (all P < 0.001) and -0.74% for sitagliptin. FPG was reduced by -16 to -27 mg/dL, and body weight was reduced by -23 to -34%, with significant increases in urinary glucose-to-creatinine ratio. Adverse events were transient, mild to moderate, and balanced across arms except for a non-dose-dependent increase in symptomatic genital infections with canagliflozin (3-8%) versus placebo and sitagliptin (2%). Urinary tract infections were reported without dose dependency in 3-9% of canagliflozin, 6% of placebo, and 2% of sitagliptin arms. Overall incidence of hypoglycemia was low. CONCLUSIONS-Canagliflozin added onto metformin significantly improved glycemic control in type 2 diabetes and was associated with low incidence of hypoglycemia and significant weight loss. The safety/tolerability profile of canagliflozin was favorable except for increased frequency of genital infections in females.
引用
收藏
页码:1232 / 1238
页数:7
相关论文
共 16 条
[1]  
[Anonymous], ANN MED 0415
[2]   Approach to renal tubular disorders [J].
Arvind Bagga ;
Anurag Bajpai ;
Shina Menon .
The Indian Journal of Pediatrics, 2005, 72 (9) :771-776
[3]   Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications [J].
Bakris, George L. ;
Fonseca, Vivian A. ;
Sharma, Kumar ;
Wright, Ernest M. .
KIDNEY INTERNATIONAL, 2009, 75 (12) :1272-1277
[4]   SLC2A9 Is a High-Capacity Urate Transporter in Humans [J].
Caulfield, Mark J. ;
Munroe, Patricia B. ;
O'Neill, Deb ;
Witkowska, Kate ;
Charchar, Fadi J. ;
Doblado, Manuel ;
Evans, Sarah ;
Eyheramendy, Susana ;
Onipinla, Abiodun ;
Howard, Philip ;
Shaw-Hawkins, Sue ;
Dobson, Richard J. ;
Wallace, Chris ;
Newhouse, Stephen J. ;
Brown, Morris ;
Connell, John M. ;
Dominiczak, Anna ;
Farrall, Martin ;
Lathrop, G. Mark ;
Samani, Nilesh J. ;
Kumari, Meena ;
Marmot, Michael ;
Brunner, Eric ;
Chambers, John ;
Elliott, Paul ;
Kooner, Jaspal ;
Laan, Maris ;
Org, Elin ;
Veldre, Gudrun ;
Viigimaa, Margus ;
Cappuccio, Francesco P. ;
Ji, Chen ;
Iacone, Roberto ;
Strazzullo, Pasquale ;
Moley, Kelle H. ;
Cheeseman, Chris .
PLOS MEDICINE, 2008, 5 (10) :1509-1523
[5]   Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006 [J].
Cheung, Bernard M. Y. ;
Ong, Kwok Leung ;
Cherny, Stacey S. ;
Sham, Pak-Chung ;
Tso, Annette W. K. ;
Lam, Karen S. L. .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (05) :443-453
[6]   Sodium-glucose transporter-2 inhibition as an antidiabetic therapy [J].
Ferrannini, Ele .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (07) :2041-2043
[7]   Risk factors for symptomatic urinary tract infection in women with diabetes [J].
Geerlings, SE ;
Stolk, RP ;
Camps, MJL ;
Netten, PM ;
Collet, TJ ;
Hoepelman, AIM .
DIABETES CARE, 2000, 23 (12) :1737-1741
[8]   Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status [J].
Goswami, R ;
Dadhwal, V ;
Tejaswi, S ;
Datta, K ;
Paul, A ;
Haricharan, RN ;
Banerjee, U ;
Kochupillai, NP .
JOURNAL OF INFECTION, 2000, 41 (02) :162-166
[9]   EFFECTS OF WEIGHT-LOSS AND REDUCED HYPERGLYCEMIA ON THE KINETICS OF INSULIN-SECRETION IN OBESE NONINSULIN DEPENDENT DIABETES-MELLITUS [J].
GUMBINER, B ;
POLONSKY, KS ;
BELTZ, WF ;
GRIVER, K ;
WALLACE, P ;
BRECHTEL, G ;
HENRY, RR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (06) :1594-1602
[10]   Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects [J].
Komoroski, B. ;
Vachharajani, N. ;
Boulton, D. ;
Kornhauser, D. ;
Geraldes, M. ;
Li, L. ;
Pfister, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (05) :520-526